Abstract
To better identify patients at high risk for cardiovascular events, several markers of risk have been proposed for use in screening. Recently, oxidative stress and inflammation have been evaluated as potential tools for prediction of the risk of cardiovascular events. Among them, we have measured reactive oxygen species (ROS) formation by polymorphonuclear cells (PMNs) and mononuclear cells (MNCs), since they may be a possible link between inflammation and oxidative stress. ROS formation by PMNs and MNCs was measured by a gated flow cytometric assay. Such biotechnological method of measuring ROS formation by PMNs and MNCs will make it possible that we measure vascular oxidative stress and vascular inflammation at the same time from only small amount of blood. We will state in this review that ROS formation by PMNs and MNCs are regulated by different mechanisms, although PMNs and MNCs are circulating in the same blood. Moreover, we will state that ROS formation by PMNs are regulated by blood pressure, Hb A 1C and oxidided LDL. ROS formation by MNCs are regulated by vascular inflammation, and that ROS formation by MNCs are also related to various cardiovascular risks such as LV mass, norepinephrine, IMT, and nocturnal blood pressure.
Keywords: Leukocytes, Cardiovascular events, Inflammation, Risk factors
Current Pharmaceutical Biotechnology
Title: Reactive Oxygen Species Formation by Polymorphonuclear Cells and Mononuclear Cells as a Risk Factor of Cardiovascular Diseases
Volume: 7 Issue: 2
Author(s): Kenichi Yasunari, Takanori Watanabe and Munehiro Nakamura
Affiliation:
Keywords: Leukocytes, Cardiovascular events, Inflammation, Risk factors
Abstract: To better identify patients at high risk for cardiovascular events, several markers of risk have been proposed for use in screening. Recently, oxidative stress and inflammation have been evaluated as potential tools for prediction of the risk of cardiovascular events. Among them, we have measured reactive oxygen species (ROS) formation by polymorphonuclear cells (PMNs) and mononuclear cells (MNCs), since they may be a possible link between inflammation and oxidative stress. ROS formation by PMNs and MNCs was measured by a gated flow cytometric assay. Such biotechnological method of measuring ROS formation by PMNs and MNCs will make it possible that we measure vascular oxidative stress and vascular inflammation at the same time from only small amount of blood. We will state in this review that ROS formation by PMNs and MNCs are regulated by different mechanisms, although PMNs and MNCs are circulating in the same blood. Moreover, we will state that ROS formation by PMNs are regulated by blood pressure, Hb A 1C and oxidided LDL. ROS formation by MNCs are regulated by vascular inflammation, and that ROS formation by MNCs are also related to various cardiovascular risks such as LV mass, norepinephrine, IMT, and nocturnal blood pressure.
Export Options
About this article
Cite this article as:
Yasunari Kenichi, Watanabe Takanori and Nakamura Munehiro, Reactive Oxygen Species Formation by Polymorphonuclear Cells and Mononuclear Cells as a Risk Factor of Cardiovascular Diseases, Current Pharmaceutical Biotechnology 2006; 7 (2) . https://dx.doi.org/10.2174/138920106776597612
DOI https://dx.doi.org/10.2174/138920106776597612 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nano Approaches to Enhance Pharmacokinetic and Pharmacodynamic Activity of Plant Origin Drugs
Current Nanoscience Atrial Fibrillation Following Cardiac Surgery: Established and Emerging Strategies of Prevention
Recent Patents on Cardiovascular Drug Discovery Subject Index To Volume 7
Current Pharmaceutical Design Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem
Current Cardiology Reviews Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design The Influence of Microneedles on the Percutaneous Penetration of Selected Antihypertensive Agents: Diltiazem Hydrochloride and Perindopril Erbumine
Current Drug Delivery The Molecular Basis of the Interplay between Endothelin-1 and Nitric Oxide and its Relevance for Atherosclerosis and Arterial and Pulmonary Hypertension
Vascular Disease Prevention (Discontinued) The Critical Roles of HSC70 in Physiological and Pathological Processes
Current Pharmaceutical Design Platelets and Atherothrombosis: Causes, Targets and Treatments for Thrombosis
Current Medicinal Chemistry NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs
Current Topics in Medicinal Chemistry The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Roles of UDP-Glucuronosyltransferases in Phytochemical Metabolism of Herbal Medicines and the Associated Herb-Drug Interactions
Current Drug Metabolism Vesicle Trafficking, Autophagy and Nanoparticles: A Brief Review
Current Nanomedicine Matrix Metallopropteinases in Heart Failure
Current Topics in Medicinal Chemistry Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin
Current Diabetes Reviews Carbohydrate Reward and Psychosis: An Explanation For Neuroleptic Induced Weight Gain and Path to Improved Mental Health?
Current Neuropharmacology Renal Phosphate Handling in Antiretroviral-naive HIV-Infected Patients
Infectious Disorders - Drug Targets Garlic for Cardiovascular Disease: Prevention or Treatment?
Current Pharmaceutical Design Editorial [Hot Topic: Cardiovascular Risk and Inflammation: Pathophysiological Mechanisms, Drug Design, and Targets Executive (Guest Editor: Armen Yuri Gasparyan)]
Current Pharmaceutical Design